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Anatomically, uterine neoplasms may be localized at 
the corpus, isthmus (the transition between the 
endocervix and uterine corpus) and cervix. The 
fallopian tubes and uterine ligaments may also undergo 
tumour tranformation. This overview will focus on 
uterine cervix and corpus tumours, including benign, 
pre-malignant and malignant lesions. They may affect 
the endometrium, muscles or other supporting tissue. 
Uterine tumours may be histologically typed according 
to several classification systems. Those used most 
frequently are based on the WHO (World Health 
Organization) International Histological Classification 
of Tumours and on the ISGYP (International Society of 
Gynecological Pathologists). The most widely-accepted 
staging system is the FIGO (International Federation of 
Gynecology and Obstetrics) one. 
Classification 
According to WHO recommendations, the main 
UTERINE CERVIX categories are:  
- Epithelial tumours, 
- Mesemchymal tumours, 
- Mixed epithelial and mesenchymal tumours, 
- Secondary tumours. 
The main UTERINE CORPUS categories, once again 
according to WHO recommendations, are: 
- Epithelial tumours, 
- Mesenchymal tumours, 
- Mixed epithelial and mesenchymal tumours, 
- Trophoblastic tumours, 
- Secondary tumours. 
 
 
Clinics and pathology 
Note 
Female pelvic gynaecological malignancies account for 
almost 15% of all cancers in women. Uterine cancer is 
the most common, specifically endometrial cancer of 
the uterine corpus. 
UTERINE CERVIX NEOPLASIA 
Note 
In countries that have well-developed screening 
programs using the Papanicolaou smear test to detect 
premalignant lesions, the incidence of invasive cervi al 
cancer continues to decline. Age-standardised 
incidence rates vary from about 10 per 100,000 in most 
developed countries to more than 40 (up to 100) per 
100,000 in many of the developing countries. 
Worldwide, invasive cervical cancer is the second most 
common female malignancy after breast cancer, with 
500,000 new cases diagnosed each year. Among benign 
lesions, endocervical polyps are the most common, 
while among malignant lesions, account for 
approximately 90%, and adenocarcinomas for 
approximately 10% of cervical cancers. Due to 
considerable ongoing evolution in understanding the 
pathobiology of cervix precursor lesions, there is a lack 
of uniform clinical, cytological and histological 
terminology, the most widely accepted being the 
modifications incorporated into the Bethesda System of 
cytological diagnosis. 
Etiology 
Carcinomas of the uterine cervix are thought to arise 
from precursor lesions, and different subtypes of 
human papilloma virus (HPV) are major etiological 
factors in disease pathogenesis. Only certain types of  
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HPV cause cervical cancer: HPV 16, 18, 33, 35, 45, 56, 
called "high-risk" types, are associated with high-grade 
Squamous Intraepithelial Lesions (SIL) and invasive 
carcinomas, whereas "low- risk" HPV 6, 11, 42, 44 are 
associated with genital condyloma and low-grade SIL. 
5% of cervical cancers are HPV DNA-negative. 
Epidemiology 
Epidemiologic studies report that factors increasing the 
likelihood of exposure to HPV, such as young age at 
first intercourse, a large number of sexual partners, 
race, high parity and low socioeconomic status, favour 
cervical cancer development. Latin America, the 
Caribbean, southern Asia, Southeast Asia, and sub-
Saharan Africa are areas with the highest incidence. 
Clinics 
Early cervical cancer is usually asymptomatic. 
Approximately 80-90% of patients with cervical cancer 
experience abnormal vaginal bleeding. HPV causes a 
large spectrum of lesions ranging from relatively 




Endocervical polyp is the most common benign lesion 
found in the uterine cervix. It appears as a focal 
hyperplastic protrusion of the endocervical folds, 
including the epithelium and the stroma. 
Microscopically, a variety of histologic patterns are 
observed, depending on the prevalence of the tissue 
type. In situ or invasive carcinomas do not usually rise 
from this lesion. 
Fibroepithelial polyp, or stromal polyp, is a benign 
exophytic proliferation of the cervical stroma. It is
composed of stellate-shaped cells growing chaotically, 
covered by stratified squamous epithelium, and is often 
seen in pregnant women. 
Microglandular hyperplasia is a common cervical 
lesion associated with oral contraception or with 
pregnancy in young women. 
Squamous intraepithelial lesion (SIL) is a precursor 
of squamous cell carcinoma and usually remains 
inactive for more than 20 years before it becomes 
invasive. SIL usually affects the transformation zone 
near the endocervical epithelium. 
Three different diagnostic systems are used:  
- CIN (Cervical Intraepithelial Neoplasia, CIN I, CIN 
II, CIN III), 
- SIL (Low grade SIL -LSIL - High grade SIL - HSIL), 
- Mild, Moderate or Severe Dysplasia. 
These systems correspond to: 
CIN I / LSIL / Mild dysplasia 
CIN II / Moderate dysplasia 
CIN III / Severe dysplasia 
CIN II and CIN III / HSIL 
Adenocarcinoma In Situ (AIS) is a precursor of 
invasive cervical adenocarcinoma, showing 
endocervical glandular atypia. 30-60% of AIS are 
associated with SIL. 50-90% of cases are associated 
with HPV 16 or 18. 
Squamous cell carcinoma (SCC) accounts for 80-90% 
of all cervical malignancies and for 60-80 % of 
invasive carcinomas. There are two major forms: 
microinvasive and invasive SCC. Diagnosis of the 
former is based on the presence of microinvasion foci.
The invasive form may show heterogeneity at the 
microscopic level, and in most cases, infiltrating nests 
and clusters are characterised by an irregular, ragged 
contour. 
Adenocarcinoma accounts for 5-20% of all cervical 
malignancies, and has increased during the past 20-30 
years, particularly among women under 35. The tumour 
possibly originates from the pluripotential cells of the 
subcolumnar endocervical epithelium. It appears in a 
variety of histologic patterns, including mucinous, 
endometrioid, clear cell, well- differentiated 
villoglandular and serous adenocarcinoma. 
Mesenchymal neoplasia: 
Leiomyomas are rarer than those appearing in the 
uterine corpus and have a similar macroscopical and 
microscopical appearence. They account for 
approximately 8% of all uterine smooth muscle tumors. 
Leiomyosarcoma is very rare. 
Mixed epithelial and mesenchymal neoplasia: 
Adenomyoma and papillary adenofibromas are rare 
polyp-like lesions composed of an admixture of 
fibroconnective tissue, smooth muscle and glandular 
elements. Adenomyomas may recur but behave 
benignly. 
Malignant Mullerian Mixed Tumour (MMMT) is 
rarely seen in the cervix, compared with its much more 
common uterine counterpart. This lesion occurs in 
postmenopausal women and typically forms polypoid 
or peduncolated masses. Its histologic appearence 
differs from that of its uterine counterpart. 
Mullerian adenosarcoma is rare. It is microscopically 
characterized by papillae covered by typical 
endocervical epithelium and malignant mesenchymal 
elements. 
Secondary tumours are uterine cervix tumours 
originating outside the cervix. 
Treatment 
Precancerous changes in the cervix may be treated wi h 
cryosurgery, cauterization or laser surgery. Cervical 
conization may eventually prove to be therapeutic in 
many patients. Depending on the stage of the disease, 
surgery (early invasive cancer), combined with 
radiation, thermotherapy or chemotherapy (more 
advanced cases), are treatments of choice. 
Prognosis 
Early-stage cervical cancer and precancerous cervical 
conditions are almost 100% curable. The five-year 
relative survival rate for earliest-stage cervical c ncer is 






Atlas Genet Cytogenet Oncol Haematol. 2005; 9(1)  
 
47 
91%. Although death rates fell by 74% between 1955 
and 1992 and continue to drop by about 2% a year, 
invasive cervical cancer continues to register 
significant morbidity and is a major cause of cancer 
deaths in women worldwide. Very recently, a 
"predictive score" system that separates the 
thermoradiosensitive group from the 
thermoradioresistant group of advanced cervical cancer 
has been developed on the basis of the expression 
profiles of 35 genes, selected by cDNA microarray 
analysis. 
UTERINE CORPUS NEOPLASIA  
Note 
Uterine cancer is the fourth most common malignancy 
in women, following breast cancer, lung and colorectal 
cancer. However, as it is usually detected in early 
stages, it is not a common cause of cancer deaths. The 
most common corpus malignancy is the endometrial 
carcinoma (approximately 95 %.); sarcomas represent 
only 4% and heterologous tumors such as 
rhabdomyosarcomas, osteosarcomas and 
chondrosarcomas the remaining 1%. 
The most common corpus benign tumor is leiomyoma, 
a proliferation of mesenchymal origin, occurring in 
approximately 77% of women of reproductive age, 
according to a study on serial uterine sections. 
Etiology 
The main risk factors for uterine corpus malignancy are 
obesity, nulliparity, late menopause, diabetes, and 
hypertension and radiation therapy. 10-25% of patients 
with mesenchymal malignancy report the 
administration of pelvic radiation 5 to 25 years earli r. 
Benign endometrial neoplasia, such as endometrial 
polyps, hyperplasia and adenocarcinoma, may be 
associated with tamoxifen therapy, possibly mediate 
through its agonistic estrogenic properties. As rega ds 
leiomyoma, evidence supports genetic susceptibility. 
Concerning gestational trophoblastic diseases, 
hydatiform moles arise from abnormal conceptions and 
most choriocarcinoma and placental site trophoblastic 
tumours develop following complete moles. 
Epidemiology 
The incidence of uterine malignancy varies widely 
throughout the world, with lower rates occurring in 
developing countries and higher rates in industrialized 
ones. 
Benign neoplasia, specifically leiomyomas, most 
commonly occurs in women aged 35-49 years, but can 
be seen at any time between menarche and menopause. 
They are more common in black than in white women 
(3-9:1). 
Clinics 
Onset is frequently accompanied by metrorrhagia, 
menometrorrhagia, spotting and irregular bleeding, for  
both benign and malignant lesions, including 
trophoblastic diseases. Early pathological proliferation 
may sometimes be asymptomatic. Pain and pelvic 




Endometrial polyps are present in 24% of the general 
female population, mainly in women over 40 years of 
age. They may show morphologically diverse patterns, 
related to patient hormone status, and consist of 
hyperplastic, cystically dilated glands in a fibrous 
stroma with large, thick-walled blood vessels. 
Endometrial polyps originate from monoclonal 
proliferation of mesenchyme and are not precancerous 
lesions, but endometrial epithelial invasive cancer 
(EIC) may be found in benign endometrial polyps, and
endometrial polypoid masses may be malignant 
(adenosarcoma, malignant Mullerian mixed - MMMT -
, endometrial stromal tumor). They may be associated 
with long-term tamoxifen therapy. 
Endometrial hyperplasia (EH) is defined as a 
proliferation of glands of irregular size and shape with 
an increased gland/stroma ratio compared with 
proliferative endometrium. Morphologic alterations 
range from benign changes to premalignant disease. EH 
develops as a result of unopposed extrogenic 
stimulation. Association with polycystic ovarian 
disease has been described, but this entity is still a 
subject of debate. The WHO classification (adopted in 
1994 and currently in use) distinguishes: typical 
(simple and complex) and atypical (simple and 
complex) hyperplasias. The latter confers signifcantly 
higher risk of progression to arcinoma. 
Intraepithelial Carcinoma (EIC) is characterized by 
markedly atypical nuclei, identical to those seen in 
invasive serous carcinoma 
Endometrial carcinoma is defined as an epithelial 
tumor, usually with glandular differentiation, arising in 
the endometrium and which has the potential to invade 
the myometrium and spread to distant sites. Type-I 
(related to estrogen) and Type-II (unrelated to estrogen) 
lesions are distinguished with respect to their biology 
and clinical course. Endometrioid carcinoma and 
serous carcinoma are the respective prototypes of the 
two groups. Major genetic alterations (see genes) sem 
to distinguish the two types, and histological 
classification of endometrial carcinoma may currently 
benefit from molecular analysis. 
Endometrioid carcinoma is the most common 
endometrial malignancy, accounting for more than 75% 
of all endometrial cancers, and is relatively rare in pre-
menopausal women. The histologic pattern resembles 
proliferative-phase endometrium and has less than 10%
of squamous, serous, mucinous or clear differentiation. 
Both architectural and nuclear appearence are 
unavoidable criteria for grading lesions 
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Serous carcinoma is a highly aggressive carcinoma, 
usually post-menopausal, accounting for 10% of 
endometrial carcinomas. Geographical distribution is 
worldwide, although a lower incidence is reported in 
Norway and Australia. Papillary architecture with cells 
showing marked cytologic atypia is common. 
Clear cell carcinoma comprises 1.6% of all uterine 
carcinomas and may have different architectural 
patterns, such as solid, papillary tubular and cysti . 
Mucinous carcinoma is defined by the presence of 
more then 50% of cells containing periodic acid-Shiff 
positive, diastase-resistant intracytoplasmic mucin. It is 
rare, and usually has a glandular architectural pattern. 
Squamous cell carcinoma is extremely rare and is 
microscopically similar to its cervix counterpart 
Mixed carcinoma is defined as an endometrial 
carcinoma showing at least one other component 
comprising at least 10% of the tumour. 
Transitional cell carcinoma is very rare and is defined 
by the presence of more than 90% of cells resembling 
urothelial transitional cells. 
Small cell carcinoma is very uncommon and 
resembles small cell carcinoma of the lung. 
Undifferentiated carcinoma includes approximately 
1-2% of tumours lacking either glandular or squamous 
differentiation.  
Mesenchymal neoplasia: 
These tumours arise primarily from two distinct tissues: 
myometrial muscle (leiomyosarcoma) and endometrial 
stroma (mesodermal and stromal sarcomas). 
Leiomyoma is a very common uterine smooth muscle 
proliferation, usually detected in women over 30 years 
old. Its growth is hormone- dependent and typical 
nodules are composed of whorled, anastomosing 
fascicles of smooth muscle cells. Less typical lesion  
are grouped into specific subtypes. 
Endometrial stromal nodule is a rare lesion present in 
women aged 23-75 years. The lesion may protrude into 
the uterine cavity or grow within the myometrium. 
Microscopically, the cells resemble normal 
proliferative-phase endometrial stromal cells. The 
lesion is benign, but a hysterectomy may be necessary 
in order to evaluate the margin. 
Leiomyosarcoma accounts for 1.3% of all uterine 
malignancies. Most of them are intramural, and nuclear 
atypia, high mitotic index and cell necrosis are th main 
diagnostic criteria. 
Endometrial stromal sarcoma (ESS) is a rare tumor 
(0.2% of all uterine cancers) invading, by definition, 
the miometrium. It is typically subdivided into low-
grade (fewer than 5-10 mitoses per 10 HPF and 
minimal cellular atypia) and high-grade stromal 
sarcoma, although this division has recently been 
questioned. 
Miscellaneous mesenchymal tumors show no 
predominant muscle smoot or stromal differentiation 
and comprise: endometrial stromal and smooth muscle  
tumour (composed of an admixture of endometrial 
stromal and smooth muscle cells), adenomatoid tumour 
(a benign lesion of the uterine serosa and myometrium 
originating from the mesothelium and forming gland-
like structures), other rare mesenchymal tumours 
(benign and malignant, such as lipoma, haemangioma, 
limphangioma, rhabdomyoma, rhabdomyosarcoma, 
liposarcoma, osteosarcoma, alveolar soft part sarcoma, 
etc) histologically identical to their counterparts arising 
in the usual sites. 
Mixed epithelial and mesenchymal neoplasia:  
Adenofibroma usually occurs in postmenopausal 
women and tends to recur. It presents an admixture of 
epithelial and mesenchymal cells. 
Carcinofibroma is a very rare lesion whose behaviour 
is not yet clear. It is composed of an admixture of 
malignant epithelial and benign mesenchymal cells. 
Adenosarcoma is a rare biphasic tumour which may 
occur at any age. It is a low-grade neoplasm, with a 
potential for recurrence and metastasis. It is 
charaterized by benign epithelial and saromatous 
mesenchymal components. 
Carcinosarcoma (malignant mixed mesodermal 
sarcoma - MMMT), is still a debated entity: formerly 
classified among sarcomas, nowadays it is considered a 
variant of carcinoma, on the basis of recent clinical, 
histopathological, cytogenetic and molecular evidence. 
It accounts for 5% of all uterine corpus malignancies 
and is found in postmenopausal women. 
Microscopically it shows an admixture of 
carcinomatous and sarcoma-like elements, resulting in 
a characteristic biphasic appearance. It appears as a
large, soft, polypoid mass involving the endometrium 
and myometrium. The carcinomatous component may 
be composed of papillary serous, endometrioid or clear 
cells, the stromal component of round or spindle cels. 
Gestational trophoblastic tumors: 
Gestational trophoblastic tumors are neoplastic 
disorders arising from placental trophoblastic tissue 
after abnormal fertilization. 
Partial hydatiform mole is an abnormal placenta 
grossly characterised by an admixture of normal and
hydropic chorionic villi. 
Complete hydatiform mole is an abnormal placenta 
characterised by abnormal throphoblastic proliferation 
involving most chorionic villi. 
Invasive hydatiform mole, usually subsequent to a 
complete mole, is composed of hydatiform mole villi 
within the myometrium. 
Gestational choriocarcinoma is a highly malignant, 
often metastatizing neoplasm composed of a disordered 
array of syncytiotrophoblastic and cytotrophoblastic 
elements, without chorionic villi. 
Placental site tumour is a rare neoplasm deriving from 
intermediate trophoblast cells in the placenta. 
Secondary tumours are uterine corpus tumours 
originating outside the uterus. 










The vast majority of uterine corpus malignant tumours 
are highly curable since they present early symptoms 
and may often be diagnosed precociously. Knowledge 
of the surgicopathologic, as well as clinical, staging is 
crucial in developing an appropriate management plan. 
Surgical therapy is usually necessary for the majority f 
endometrial malignancies. Other adjuvant/adjunctive 
therapies such as radiation therapy, chemotherapy and 
hormonal therapy may be considered. 
Treatment for benign uterine corpus lesions depends o  
the symptoms, tumor size and location and age of the 
patient. 
Prognosis 
Prognostic significance of hormone receptors in 
endometrial cancer has been reported; moreover, 
immunohistochemistry for both estrogen and 
progesterone receptors has been shown to correlate 
with FIGO grade as well as survival. HER-2/neu 
overexpression has been reported to be associated with 
a poor prognosis. Endometrioid adenocarcinoma and 
adenosquamous carcinoma have the highest overall 5-
year survival rates. (respectively 76% and 68%), clear 
cell and papillary serous carcinomas the lowest 
(respectively 51% and 46%). The evolution of sarcoma 
depends primarily on the extent and stage of the dis ase 
at diagnosis. Recurrences are very frequent. The overall 
5-year survival rate is 15-25%.  
Among benign neoplasias, endometrial polyps may 
undergo malignant tranformation, while leiomyomas 
usually do not. 
Cytogenetics 
Note 
The vast majority of endometrial cancers are sporadic. 
However, hereditary predisposition to develop uterin  
carcinoma is associated with hereditary non-polyposis 
colorectal carcinoma (HNPCC) and Cowden syndrome. 
Germline mutations of the FH (fumarate hydratase) 
have been found to be involved in syndromes 
associated with uterine leiomyomas. Evidence supports 
the existence of genetic factors predisposing to non-
syndromic uterine leiomyoma, although susceptibility 
genes have not yet been identifed. 
Cytogenetics Morphological 
UTERINE CERVIX: 
Karyotypic analysis on uterine cervix lesions is limited. 
No specific chromosome changes have been reported, 
although most lesions show cytogenetic abnormalities, 
including polyploidy. Chromosomes 5 and 17 are those 
most frequently involved in changes in carcinomas. 
UTERINE CORPUS:  
Endometrial polyps may show abnormal karyotypes, 
usually with a single or few changes. Three main 
cytogenetically-abnormal subgroups have been 
observed: (a) rearrangements in the 6p21-p22 region; 
(b) rearrangements in the 12q13-15 region; (c) 
rearrangements in the 7q22 region. At least for the 
subgroup with 6p21 rearrangement, it has been 
demonstrated that karyotypically aberrant cells belong 
to the stromal component of endometrial polyps. 
Endometrial carcinomas do not show specific 
chromosome changes. Most of them are characterized 
by a hyperdiploid modal chromosome number. The 
majority show numerical chromosome changes, but 
cases with both numerical and structural abnormalities 
have been observed in the context of complex 
karyotypes. Non-random gains of 1q and 8q are 
frequently found. Correlations between karyotypic 
aberration patterns and histological differentiation have 
recently been reported, with the identification of 
different copy number changes among the different 
grades of type I carcinomas, between serous papillary 
and clear-cell carcinomas of type II, as well as betwe n 
homologous and heterologous carcinosarcomas. 
Endometrial stromal tumours are cytogenetically 
heterogeneous. The most common karyotypic changes 
involve chromosomes 6, 7, and 17. A subgroup of 
stromal lesions, including low-grade endometrial 
stromal sarcomas (more rarely in high-grade ESS) and 
endometrial stromal nodules are characterized by 
t(7;17)(p15;q21) translocation, resulting in the fusion 
of JAZF1 and JJAZ1 genes. 
In Endometrial Malignant Mullerian Mixed 
Tumours, chromosome 8 or 8q. gains have been 
suggested to characterize a distinct cytogenetic 
subgroup. 
Benign smooth muscle tumors are associated with 
abnormal karyotypes in almost 40-60% of cases. 
Different cytogenetically-abnormal subgroups have 
been recognized. Chromosomal structural changes at 
the 6p21, 12q13-15; 7q22,  and trisomy 12 define those 
most frequently found; chromosome regions 1q42-44, 
3q, and 10q are non-randomly involved in changes in a 
minority of cases. 
Uterine leiomyosarcomas have complex cytogenetic 
karyotypes with numerical and structural aberrations 
and cytogenetic intratumoral heterogeneity. 
Hydatiform moles have peculiar karyotypes: complete 
moles usually have a 46,XX karyotype of paternal 
origin, arising from an anuclear oocyte fertilized by an 
haploid 23,X sperm which undergoes replication. More 
rarely a 46,XY karyotype is found, arising from the 
fertilizaion of an anuclear oocyte by two haploid 
sperm. Incomplete moles (more than 90%) have a 
triploid karyotype and the presence of both maternal 
and paternal chromosomal material, due to ferilizaton 
of an haploid oocyte by two haploid sperm. 
Cytogenetics Molecular 
UTERINE CERVIX. A pronounced chromosomal 
instability in advanced cervical carcinomas has been 
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observed by comparative genomic hybridization 
(CGH.). CGH profiles show 2q33-q37 deletions and 3q 
gains as characteristic changes. FISH analysis on 
squamous cell carcinoma showed an increased DNA 
copy number in chromosomes 3 and X in the 
development and progression from HSIL to cervical 
carcinoma. 
UTERINE CORPUS. CGH data on endometrial 
cancer confirm G-banding results, pinpointing a 
central role of 8q gains in the pathogenesis of 
carcinosarcomas and endometrial adenocarcinomas. 
CGH observation shows that atypical endometrial 
hyperplasia shares genomic abnormalities with 
endometrioid carcinoma, whereas simple endometrial 
hyperplasia shows no genomic imbalances. 
Genes involved and proteins 
Note 
Notch1 exerts specific protective effects against HPV-
induced transformation through suppression of E6/E7 
expression. In high-grade HPV-positive cervical 
lesions, down-regulation of the cell signaling molecule 
Notch1 allows for increased expression of E6 and E7 
oncogenes, which promote malignant cervical cell 
transformation.  
A putative progression model for sporadic 
endometrioid adenocarcinoma developing through 
atypical endometrial hyperplasia has recently been 
proposed. Tumour initiation and progression are 
characterized by the acquisition of various molecular 
alterations. In this model, the most frequent, earli st 
events are the mutation of PTEN and K-ras, possibly 
followed by inactivation of e-cadherin (playing a role 
in progression) and later by p53 mutations, 
overexpressin of her/neu and inactivation of p16. An 
alternative pathway may lead directly to a high-grade 
tumour type by p53 mutation and her2/neu 
amplification, respectively.  
Mutations in the MSH2/MSH6 complex seem to play a 
central role in endometrial carcinoma associated 
with HNPCC. 
Fusion of the JAZF1 and JJAZ1 genes is found in 
endometrial stromal lesions, possibly restricted to the 
classic histologic subset. 
Intragenic PTEN mutations are involved in the genesis 
of uterine carcinosarcomas with endometrioid-type 
carcinoma components. 
Complete moles show overexpression of several 
growth factors, including c-myc, epidermal growth 
factor, and c-erbB2, as compared to a normal placent . 
On rare occasions, complete moles may be familial, 
inherited as an autosomal trait: they are biparental i  
origin and result from misexpression of imprinted 
genes. A candidate region of chromosome arm 19q13.4 
has been identified. 
Germline mutations of the fumarate hydratase (FH) 
gene, located at 1q42.1, are involved in syndromic 
uterine leiomyomas. Very recently, loss of the FH 
gene has been demonstrated in a subgroup of 
nonsyndromic uterine leiomyoma characteried by 1q 
rearrangements. 
Dysregulation of the HMGA2 (12q15) and HMGA1 
(6p21.3) genes has been observed in uterine 
leiomyomas, as well as in endometrial polyps. 
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